Balovaptan
Phase 1Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autism Spectrum Disorder
Conditions
Autism Spectrum Disorder
Trial Timeline
Jun 26, 2022 → Oct 13, 2022
NCT ID
NCT03912350About Balovaptan
Balovaptan is a phase 1 stage product being developed by Roche for Autism Spectrum Disorder. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03912350. Target conditions include Autism Spectrum Disorder.
What happened to similar drugs?
0 of 10 similar drugs in Autism Spectrum Disorder were approved
Approved (0) Terminated (2) Active (8)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03912350 | Phase 1 | Withdrawn |
| NCT04049578 | Phase 1 | Terminated |
Competing Products
20 competing products in Autism Spectrum Disorder